bluebird bio - BLUE Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

9 equities research analysts have issued 1-year target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they predict the company's share price to reach $6.88 in the next twelve months. This suggests that the stock has a possible downside of 19.0%.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $9.99 at the beginning of the year. Since then, BLUE stock has decreased by 15.0% and is now trading at $8.49.
View the best growth stocks for 2022 here.

bluebird bio saw a decrease in short interest in November. As of November 15th, there was short interest totaling 19,270,000 shares, a decrease of 14.5% from the October 31st total of 22,540,000 shares. Based on an average daily trading volume, of 6,040,000 shares, the days-to-cover ratio is presently 3.2 days.
View bluebird bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, March 3rd 2023.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) posted its earnings results on Friday, November, 5th. The biotechnology company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.65) by $0.51. The biotechnology company had revenue of $22.70 million for the quarter, compared to analyst estimates of $39.07 million. bluebird bio had a negative net margin of 8,828.28% and a negative trailing twelve-month return on equity of 173.58%. The business's quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.94) earnings per share.

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (15.34%), BlackRock Inc. (8.32%), Tang Capital Management LLC (7.64%), Vanguard Group Inc. (4.47%), Credit Suisse AG (1.91%) and Dimensional Fund Advisors LP (1.96%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Philip D Gregory, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $8.49.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $703.91 million and generates $3.66 million in revenue each year. The biotechnology company earns $-819,380,000.00 in net income (profit) each year or ($6.10) on an earnings per share basis.

The company employs 518 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.